Figures and Tables

From the following article:

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Eugene W. M. Ng, David T. Shima, Perry Calias, Emmett T. Cunningham, Jr., David R. Guyer & Anthony P. Adamis

Nature Reviews Drug Discovery 5, 123-132 (February 2006)

doi:10.1038/nrd1955

Figure 1 - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Figure 1

A depiction of the SELEX process7.

Figure 2 - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Figure 2

Pegaptanib structure and target binding.

Figure 3 - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Figure 3

Mean visual acuity throughout 2 years.

Table 1 - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Table 1

Modifications that affect aptamer stability and affinity for VEGF

Table 2 - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Table 2

Comparison of candidate 2'-fluoropyrimidine anti-VEGF aptamers14

Table 3 - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Table 3

Additional year 1 efficacy endpoints in the VISION trials*